Bioxcel Therapeutics

BTAI45

Penny Stock

$0.58arrow_drop_down10.76%-$0.07

Penny Stock

BTAI45

$0.58

arrow_drop_down10.76%-$0.07

Penny Stock

Performance History

Key Stats
Open	$0.67
Prev. Close	$0.65
EPS	-3.46
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$25.96M
PE Ratio	-

	LOW	HIGH
Day Range	0.58	0.67
52 Week Range	0.53	5.62

Ratios







EPS	-3.46

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Bioxcel Therapeutics (BTAI)

Bioxcel Therapeutics Inc (BTAI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of neurological and immunological diseases. The company's pipeline includes several potential first-in-class or best-in-class drug candidates that target specific molecular pathways involved in these diseases. Bioxcel's approach is based on its proprietary AI-driven analytics platform, which integrates vast amounts of data to identify novel drug candidates and optimize drug development.

One of Bioxcel's lead drug candidates is BXCL501, a sublingual thin film formulation of dexmedetomidine that is being developed for the treatment of acute agitation in patients with schizophrenia and bipolar disorder. The company recently announced positive results from a Phase 3 clinical trial of BXCL501, demonstrating its potential to rapidly and effectively reduce agitation without causing excessive sedation. Bioxcel plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the near future and is also exploring additional indications for BXCL501.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Vimal D. Mehta Ph.D.
Headquarters: New Haven
Employees: 183
Exchange: NASDAQ

Keep an eye on Bioxcel Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Bioxcel Therapeutics 's (BTAI) price per share?

The current price per share for Bioxcel Therapeutics (BTAI) is $0.59. The stock has seen a price change of -$0.07 recently, indicating a -10.76% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Bioxcel Therapeutics (BTAI)?

For Bioxcel Therapeutics (BTAI), the 52-week high is $5.62, which is 860.03% from the current price. The 52-week low is $0.53, the current price is 10.45% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Bioxcel Therapeutics (BTAI) a growth stock?

Bioxcel Therapeutics (BTAI) has shown an average price growth of 0.41% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Bioxcel Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Bioxcel Therapeutics (BTAI) stock price performance year to date (YTD)?

As of the latest data, Bioxcel Therapeutics (BTAI) has a year-to-date price change of -80.02%. Over the past month, the stock has experienced a price change of -17.55%. Over the last three months, the change has been -48.65%. Over the past six months, the figure is -78.48%. Looking at a longer horizon, the five-year price change stands at -95.03%.

help

Is Bioxcel Therapeutics (BTAI) a profitable company?

Bioxcel Therapeutics (BTAI) has a net income of -$179.05M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.49K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.38M, although specific revenue growth data is currently not available. Operating income is noted at -$166.33M. Furthermore, the EBITDA is -$104.3M.

help

What is the market capitalization of Bioxcel Therapeutics (BTAI)?

Bioxcel Therapeutics (BTAI) has a market capitalization of $25.96M. The average daily trading volume is 833.12K, indicating the stock's liquidity and investor engagement.

News

BioXcel Therapeutics Announces Preliminary Estimated - GlobeNewswire

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

CALENDAR OF EVENTS

CLINICAL STUDY

4/24/2024

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting